Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,567 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 38,198 · Balance 162,567 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 202,759 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 202,759 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 156,589 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 46,170 · Balance 156,589 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 194,786 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2024 Filed Feb 23, 2024 22:51 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 111 | $17.35 | $1,925.85 |
DisclosureSEC source: 0001628280-24-006707 · wk-form4_1708728670.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,688 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,232 | $16.76 | $20,648.32 |
DisclosureSEC source: 0001628280-24-001979 · wk-form4_1706048954.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,799 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 491 | $16.75 | $8,224.25 |
DisclosureSEC source: 0001628280-24-000469 · wk-form4_1704405838.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,031 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 00:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 394 | $12.37 | $4,873.78 |
DisclosureSEC source: 0001628280-23-040673 · wk-form4_1701735258.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,522 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 15:41 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 98 | $10.77 | $1,055.46 |
DisclosureSEC source: 0001628280-23-039098 · wk-form4_1700062879.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,916 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 20:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 464 | $14.16 | $6,570.24 |
DisclosureSEC source: 0001628280-23-033496 · wk-form4_1696280188.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,014 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 21:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 347 | $10.99 | $3,813.53 |
DisclosureSEC source: 0001628280-23-030911 · wk-form4_1693345803.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,478 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:48 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 134 | $12.38 | $1,658.92 |
DisclosureSEC source: 0001628280-23-029685 · wk-form4_1692218881.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,825 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 489 | $22.91 | $11,202.99 |
DisclosureSEC source: 0001628280-23-023910 · wk-form4_1688070930.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,959 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 337 | $23.21 | $7,821.77 |
DisclosureSEC source: 0001437749-23-016546 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,448 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 15, 2023 Filed May 18, 2023 01:52 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 92 | $18.71 | $1,721.32 |
DisclosureSEC source: 0001437749-23-015002 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,785 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,545 | $20.03 | $30,946.35 |
DisclosureSEC source: 0001437749-23-009872 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,267 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed May 17, 2023 01:47 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,545 | $20.03 | $30,946.35 |
DisclosureSEC source: 0001437749-23-014859 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,877 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 3,610 shares. Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:47 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 3,610 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014859 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 3,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:47 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-014859 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 521 | $20.62 | $10,743.02 |
DisclosureSEC source: 0001437749-23-008893 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,812 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 874 | $22.75 | $19,883.50 |
DisclosureSEC source: 0001437749-23-005439 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,333 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 58 | $24.60 | $1,426.80 |
DisclosureSEC source: 0001437749-23-003203 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,207 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-002930 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 9,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,000 | $25.13 | $226,170.00 |
DisclosureSEC source: 0001437749-23-002930 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,000 | $2.06 | $18,540.00 |
DisclosureSEC source: 0001437749-23-002930 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-002930 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 1,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,000 | $25.29 | $25,290.00 |
DisclosureSEC source: 0001437749-23-002930 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 1,000 | $2.06 | $2,060.00 |
DisclosureSEC source: 0001437749-23-002930 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-001796 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 3,500 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,500 | $25.01 | $87,535.00 |
DisclosureSEC source: 0001437749-23-001796 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,500 | $2.06 | $7,210.00 |
DisclosureSEC source: 0001437749-23-001796 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 00:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-001485 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Stock · 6,500 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 00:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,500 | $25.04 | $162,760.00 |
DisclosureSEC source: 0001437749-23-001485 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.10, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 00:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,500 | $2.06 | $13,390.00 |
DisclosureSEC source: 0001437749-23-001485 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 11,885 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000820 · rdgdoc.xml · derivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,885 Underlying: Common Stock · 11,885 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 11,885 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000820 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,265 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 501 | $16.90 | $8,466.90 |
DisclosureSEC source: 0001437749-22-029956 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,380 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 50 | $23.16 | $1,158.00 |
DisclosureSEC source: 0001437749-22-027396 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,881 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 463 | $23.02 | $10,658.26 |
DisclosureSEC source: 0001437749-22-023340 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,931 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 52 | $23.17 | $1,204.84 |
DisclosureSEC source: 0001437749-22-020212 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,394 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 28, 2022 Filed Jul 1, 2022 00:06 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 495 | $14.86 | $7,355.70 |
DisclosureSEC source: 0001437749-22-016326 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,446 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 51 | $12.32 | $628.32 |
DisclosureSEC source: 0001437749-22-012845 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,941 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:16 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 13,581 | $17.59 | $238,889.79 |
DisclosureSEC source: 0001437749-22-009260 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,992 F1 · date: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · kind: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · price: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 01:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 32,136 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-008918 · rdgdoc.xml · derivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,136 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 01:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 32,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-008918 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:17 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 475 | $22.24 | $10,564.00 |
DisclosureSEC source: 0001437749-22-007913 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,437 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 14,019 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-005777 · rdgdoc.xml · derivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,019 Underlying: Common Stock · 14,019 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-005777 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,912 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 254 | $29.38 | $7,462.52 |
DisclosureSEC source: 0001437749-22-003346 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,893 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 29, 2021 Filed Dec 31, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 517 | $39.37 | $20,354.29 |
DisclosureSEC source: 0001437749-21-029530 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,147 F1 · kind: The sale reported herein was made by to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001437749-21-028268 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On August 7, 2014, the reporting person was granted an option to purchase 10,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $36.52 | $365,200.00 |
DisclosureSEC source: 0001437749-21-028268 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.74 to $37.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.62 | $26,200.00 |
DisclosureSEC source: 0001437749-21-028268 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-027005 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.